Pegloticase is used to treat chronic gout. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency who are treated with pegloticase are at risk of hemolysis and methemoglobinemia. Pegloticase is contraindicated for such patients.
Patients deficient in G6PD have reduced ability to reduce the hydrogen peroxide formed as a major byproduct of the pegloticase-catalyzed oxidation of uric acid to allantoin. Excerpt from the pegloticase (KRYSTEXXA) drug label:
Before starting KRYSTEXXA, patients at higher risk for G6PD deficiency (e.g., those of African and Mediterranean ancestry) should be screened due to the risk of hemolysis and methemoglobinemia.
For the complete drug label text with sections containing pharmacogenetic information highlighted, see the pegloticase drug label.
*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.